Tags

Type your tag names separated by a space and hit enter

The changing and dynamic epidemiology of meningococcal disease.
Vaccine. 2012 May 30; 30 Suppl 2:B26-36.V

Abstract

The epidemiology of invasive meningococcal disease continues to change rapidly, even in the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease caused by serogroup C has been achieved in countries that have implemented meningococcal C or quadrivalent meningococcal ACWY conjugate vaccines. Initiation of mass immunization programs with meningococcal A conjugate vaccines across the meningitis belt of Africa may lead to the interruption of cyclical meningococcal epidemics. A meningococcal B vaccination program in New Zealand has led to a decreased incidence of high rates of endemic serogroup B disease. Increases in serogroup Y disease have been observed in certain Nordic countries which, if they persist, may require consideration of use of a multiple serogroup vaccine. The imminent availability of recombinant broadly protective serogroup B vaccines may provide the tools for further control of invasive meningococcal disease in areas where serogroup B disease predominates. Continued surveillance of meningococcal disease is essential; ongoing global efforts to improve the completeness of reporting are required.

Authors+Show Affiliations

Canadian Center for Vaccinology, Dalhousie University, the IWK Health Centre, and Capital Health, Halifax, Canada. scott.halperin@dal.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22178525

Citation

Halperin, Scott A., et al. "The Changing and Dynamic Epidemiology of Meningococcal Disease." Vaccine, vol. 30 Suppl 2, 2012, pp. B26-36.
Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30 Suppl 2:B26-36.
Halperin, S. A., Bettinger, J. A., Greenwood, B., Harrison, L. H., Jelfs, J., Ladhani, S. N., McIntyre, P., Ramsay, M. E., & Sáfadi, M. A. (2012). The changing and dynamic epidemiology of meningococcal disease. Vaccine, 30 Suppl 2, B26-36. https://doi.org/10.1016/j.vaccine.2011.12.032
Halperin SA, et al. The Changing and Dynamic Epidemiology of Meningococcal Disease. Vaccine. 2012 May 30;30 Suppl 2:B26-36. PubMed PMID: 22178525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The changing and dynamic epidemiology of meningococcal disease. AU - Halperin,Scott A, AU - Bettinger,Julie A, AU - Greenwood,Brian, AU - Harrison,Lee H, AU - Jelfs,Jane, AU - Ladhani,Shamez N, AU - McIntyre,Peter, AU - Ramsay,Mary E, AU - Sáfadi,Marco A P, Y1 - 2011/12/15/ PY - 2011/10/24/received PY - 2011/12/04/revised PY - 2011/12/05/accepted PY - 2011/12/20/entrez PY - 2011/12/20/pubmed PY - 2012/9/14/medline SP - B26 EP - 36 JF - Vaccine JO - Vaccine VL - 30 Suppl 2 N2 - The epidemiology of invasive meningococcal disease continues to change rapidly, even in the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease caused by serogroup C has been achieved in countries that have implemented meningococcal C or quadrivalent meningococcal ACWY conjugate vaccines. Initiation of mass immunization programs with meningococcal A conjugate vaccines across the meningitis belt of Africa may lead to the interruption of cyclical meningococcal epidemics. A meningococcal B vaccination program in New Zealand has led to a decreased incidence of high rates of endemic serogroup B disease. Increases in serogroup Y disease have been observed in certain Nordic countries which, if they persist, may require consideration of use of a multiple serogroup vaccine. The imminent availability of recombinant broadly protective serogroup B vaccines may provide the tools for further control of invasive meningococcal disease in areas where serogroup B disease predominates. Continued surveillance of meningococcal disease is essential; ongoing global efforts to improve the completeness of reporting are required. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22178525/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)01955-4 DB - PRIME DP - Unbound Medicine ER -